Disease Diagnosis TRIZ Cases

Assessing non-combustible tobacco risks requires evaluating immune suppression via cytokine secretion analysis.

A spiral microfluidic device separates and focuses cardiac cells from whole blood using inertial migration forces.

Segmented protein biochips detect multiple marker proteins simultaneously, resolving the trade-off between diagnostic reliability and method complexity.

Antibody conjugated heavy metal probes resolve the contradiction between measurement precision and single-cell analysis capability in biological samples.

A biomarker panel method predicts sepsis risk by measuring specific molecule levels in patient samples.

Extracting CD markers from intact cells into bodily fluids enables non-invasive disease monitoring without sacrificing detection accuracy.

Acid pretreatment exposes 5hmC epitopes in fixed tissue, enabling precise quantification that distinguishes cancer from normal states.

Measuring copeptin levels predicts nocturnal enuresis treatment response, avoiding side effects in non-responders.

Identifying elevated cardiac myosin binding protein C concentrations enables rapid detection of acute myocardial infarction.

Immunoassay detects PAPP-A proteoforms in blood to estimate gestational age, replacing ultrasound equipment.

A 1,25-dihydroxyvitamin D to parathyroid hormone ratio predicts worsening renal function risk in patients.

ESM-1 biomarker levels assess silent brain infarcts to resolve the trade-off between MRI detection accuracy and screening cost.

Volatile organic compound profiling in exhaled breath enables non-invasive colorectal cancer diagnosis using mass spectrometry.

Protein G and streptavidin complexes extract IgG to eliminate competition, enabling accurate allergen-specific IgE detection.

Computer-based method analyzes optical density of membrane and cytoplasm staining to determine predicted efficacy scores for antibody drug conjugate therapies.

PME-CD40L mature dendritic cells stimulate production of stem cell memory T cells for adoptive transfer therapy.

Screening urine metabolites replaces invasive blood tests and complex exercise protocols, enabling accurate AMS severity prediction at sea level.

A serum biomarker panel using LC-MS/MS identifies Complement C3 levels to classify prostate cancer progression.

Interleukin-34 capture separates regulatory T cells from effector contamination, yielding high-purity populations for immune tolerance therapies.

Chitinase-3-like protein 1 detects acute kidney injury before serum creatinine rises, resolving early detection delays.

Expanding invariant NKT cells enables precise detection of the CD4-negative subpopulation to categorize donor risk profiles.

A multiomics platform analyzes blood and breath samples to identify ASD biomarkers with high accuracy.

Segmenting protein and glycan components improves diagnostic specificity beyond traditional PSA methods.

Immunoblotting detects autoantibodies against neural antigens, providing objective diagnostic markers for autism spectrum disorder risk.

NT-proBNP and NT-proANP biomarkers enable differential diagnosis of lung embolism types through quantitative serum analysis.

NMR spectroscopy detects LP-X via deconvolution models, replacing laborious electrophoresis to improve diagnostic accuracy.

A blood protein biomarker panel uses ultrasensitive immunoassays to detect cancer markers.

Extracting IgA autoantibodies from feces resolves the trade-off between diagnostic reliability and patient invasiveness.

Flow cytometry measures CD4+/CD8+ T cell ratios and classical monocyte levels in peripheral blood samples to identify connective tissue disease with neurological manifestations.

Measuring protein-specific oxidative damage enables targeted therapeutic screening to reduce intracellular reactive oxygen and nitrogen species.

A diagnostic method measures leukocyte migration distance and velocity to detect allergic responses in patient serum samples.

Analyzing FBXO34 subcellular distribution resolves indeterminate FNAB results, improving diagnostic accuracy while avoiding unnecessary surgeries.

Automated image processing analyzes cell dimensions and contrast to identify abnormal cells without manual operator intervention.

Fluorescent DNA-binding dyes stain sperm nuclei to measure staining intensity per unit area for fertility classification.

An NGAL assay detects neutrophil gelatinase-associated lipocalin in body fluids to predict worsening renal function in heart failure patients.

Testing circulating epithelial tumor cells from body fluids against therapeutic agents to predict response without invasive tissue sampling or long cultivation.

Segmenting biomarkers across five domains overcomes symptomatic diagnosis limitations, delivering 73-93% sensitivity for schizophrenia detection.

A urine protein biomarker multiplication method differentiates specific glomerulopathies using mass spectrometry detection.

Using segmented septin-5 polypeptides resolves low detection precision by binding autoantibodies for removal, improving diagnostic accuracy.

Segmented biomarker panels resolve low prediction accuracy by measuring glycoprotein acetyls against control values to identify gallbladder disorder risks.

Segmented antigen panels identify specific autoantibodies to overcome limited diagnostic precision in autoimmune polyglandular syndrome type 1.

Fully human antibody drug conjugates targeting CD37 replace murine antibodies to extend circulating half-life and eliminate human anti-mouse immune responses.

A dual binding agent composition isolates N-glycolylneuraminic acid from non-sialic acid components in biological samples.

PAA-specific diagnostic assays detect immune responses to identify prostatitis-associated antigens in biological samples.

TTLL11 inhibitors block enzyme activity to prevent chromosome segregation errors and aneuploidy in cancer cells.

Segmented chemical steps isolate glutathionylation signals from background thiols, enabling spatial visualization of oxidative stress markers.

Segmenting troponin, FABP3, and MYL3 kinetics clarifies injury timing and severity, enabling early aggressive intervention while reducing false positives.

Antibodies bind oxidized parathyroid hormone peptides to isolate non-oxidized intact PTH levels in patient samples.